カテゴリ： Allied Market Research, 世界, 医療/バイオ

筋骨格系障害（MSD）治療薬のグローバル市場（2023-2032）：鎮痛薬、DMARD、コルチコステロイド、その他

■ 英語タイトル：Musculoskeletal Disorders Drugs Market By Drug Type (Analgesics, DMARDs, Corticosteroids, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP123）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP123
■ 発行日：2023年4月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：263
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[筋骨格系障害（MSD）治療薬のグローバル市場（2023-2032）：鎮痛薬、DMARD、コルチコステロイド、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

筋骨格系障害（MSD）治療薬の市場規模は2022年に834億7,424万ドル、2032年には1,260億3,022万ドルに達すると推定され、2023年から2032年までの年平均成長率は4.2%です。 筋骨格系障害（MSD）は筋肉、骨、関節に影響を及ぼします。これらの障害は、身体の様々な部分に痛み、こわばり、腫れを引き起こし、日常生活を送る能力に影響を及ぼします。筋骨格系障害の症状には、関節のこわばり、腫れ、鈍痛などがあります。これらの障害は、反復運動、ぎこちない姿勢、長時間の座りっぱなしや立ちっぱなしなど、様々な要因によって引き起こされます。MSDはあらゆる年齢層の人が罹患しますが、高齢者や、スポーツ選手や肉体労働者など、筋骨格系に負担のかかる身体活動を行う人に多くみられます。最も一般的な筋骨格系障害には、関節リウマチ、骨粗鬆症、変形性関節症、線維筋痛症などがあります。

筋骨格系障害（MSD）治療薬は、筋肉、骨、関節に影響を及ぼす疾患の治療に使用される薬剤の一種です。これらの薬は、関節リウマチ、骨粗鬆症、線維筋痛症などの筋骨格系障害に伴う痛み、炎症、こわばりを緩和するのに役立ちます。筋骨格系薬剤には、鎮痛薬、コルチコステロイド、疾患修飾性抗リウマチ薬、コルチコステロイドなどいくつかの種類があります。

関節リウマチ、骨粗鬆症、強直性脊椎炎などの筋骨格系障害（MSD）の有病率の増加、筋骨格系障害（MSD）の治療に対する意識の高まりが、市場成長の要因です。労働時間の延長や運動量の増加といったライフスタイルの変化により、筋骨格系障害の発生率が高くなっています。このため、これらの症状を効果的に管理できる薬剤の需要が高まると予想されています。例えば、オーストラリア保健福祉研究所によると、2020年には5人に3人が変形性関節症と診断されると報告されています。加えて、運動器障害に罹患しやすい老年人口の増加も、これらの症状を管理する薬剤に対する高い需要をもたらし、市場の成長をさらに後押ししています。しかし、低開発国では治療が受けられないため、市場成長の妨げになることが予想されます。

さらに、生物学的製剤やバイオシミラーを含む筋骨格系障害の新薬の開発により、治療オプションの有効性と安全性が向上しました。このため、これらの薬剤の需要が増加しました。さらに、筋骨格系障害に対する住民の意識が高まり、これらの症状に対する診察や治療を求める患者が増加したことも、市場の成長を支えています。
世界の筋骨格系障害（MSD）治療薬市場は、薬剤タイプ、投与経路、流通チャネル、地域に区分されます。薬剤タイプ別では、市場は鎮痛薬、DMARDs、コルチコステロイド、その他に分類されます。投与経路ベースでは、市場は経口剤と非経口剤に二分されます。流通チャネル別では、病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、欧州のその他地域）、アジア太平洋（日本、中国、インド、オーストラリア、韓国、アジア太平洋のその他地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、LAMEAのその他地域）で分析されます。

世界の筋骨格系障害（MSD）治療薬市場で事業を展開する主な主要企業は、AbbVie Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.です。例えば、アムジェンは2022年6月、米国食品医薬品局（FDA）が中等度から重度の活動性の関節リウマチの成人患者を対象に、メトトレキサートとの併用でリツキサンに対するバイオシミラーであるRIABNI（rituximab-arrx）を承認したと発表しました。

ステークホルダーにとっての主なメリット
本レポートは、2022年から2032年までの筋骨格系障害（MSD）治療薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、有力な筋骨格系障害（MSD）治療薬市場機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益志向のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
筋骨格系障害（MSD）治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別および世界の筋骨格系障害（MSD）治療薬の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
薬剤タイプ別
鎮痛薬
DMARDs
副腎皮質ステロイド薬
その他

投与経路別
経口剤
非経口剤

流通経路別
病院薬局
オンラインプロバイダー
ドラッグストア・薬局

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主要市場プレイヤー
○ AbbVie Inc.
○ Amgen Inc.
○ Eli Lilly and Company
○ F. Hoffmann-La Roche Ltd.
○ Johnson & Johnson
○ Merck & Co., Inc.
○ Novartis AG
○ Pfizer Inc.
○ Teva Pharmaceutical Industries Ltd.
○ UCB S.A.

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：筋骨格系障害（MSD）治療薬市場、薬剤タイプ別
第5章：筋骨格系障害（MSD）治療薬市場、投与経路別
第6章：筋骨格系障害（MSD）治療薬市場、流通チャネル別
第7章：筋骨格系障害（MSD）治療薬市場、地域別
第8章：競争状況
第9章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. High prevalence of musculoskeletal (MSK) disorders
3.4.1.2. Surge in geriatric population across the globe
3.4.1.3. Increase in number of pipeline drugs

3.4.2. Restraints
3.4.2.1. Lack of treatment in emerging countries

3.4.3. Opportunities
3.4.3.1. High growth potential in emerging markets

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Analgesics
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. DMARDs
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Corticosteroids
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Parenteral
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Online Providers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Type
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Type
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Type
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Type
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Type
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Type
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Type
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Type
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Type
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Type
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Type
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Type
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Type
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Type
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Type
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Type
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Type
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Type
7.5.5.3.3. Market size and forecast, by Route of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Type
7.5.5.4.3. Market size and forecast, by Route of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. AbbVie Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Amgen Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Eli Lilly and Company
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. F. Hoffmann-La Roche Ltd.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Johnson & Johnson
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Merck & Co., Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Novartis AG
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Pfizer Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Teva Pharmaceutical Industries Ltd.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. UCB S.A.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ANALGESICS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DMARDS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR CORTICOSTEROIDS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 07. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 08. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 10. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 20. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 23. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 26. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 29. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 32. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 33. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 35. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 36. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 39. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 41. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 42. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 44. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 45. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 54. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 55. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 57. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 58. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 62. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 63. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 64. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 71. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 72. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 73. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 75. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 76. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 77. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 87. ABBVIE INC.: KEY EXECUTIVES
TABLE 88. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 89. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 90. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 91. ABBVIE INC.: KEY STRATERGIES
TABLE 92. AMGEN INC.: KEY EXECUTIVES
TABLE 93. AMGEN INC.: COMPANY SNAPSHOT
TABLE 94. AMGEN INC.: PRODUCT SEGMENTS
TABLE 95. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 96. AMGEN INC.: KEY STRATERGIES
TABLE 97. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 98. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 99. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 100. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 101. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 102. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 104. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 105. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 106. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 107. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 108. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 109. JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 110. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 111. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 112. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 113. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 114. NOVARTIS AG: KEY EXECUTIVES
TABLE 115. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 116. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 117. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 118. NOVARTIS AG: KEY STRATERGIES
TABLE 119. PFIZER INC.: KEY EXECUTIVES
TABLE 120. PFIZER INC.: COMPANY SNAPSHOT
TABLE 121. PFIZER INC.: PRODUCT SEGMENTS
TABLE 122. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 123. PFIZER INC.: KEY STRATERGIES
TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 129. UCB S.A.: KEY EXECUTIVES
TABLE 130. UCB S.A.: COMPANY SNAPSHOT
TABLE 131. UCB S.A.: PRODUCT SEGMENTS
TABLE 132. UCB S.A.: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 原発性胆汁性胆管炎（PBC）治療薬のグローバル市場（2023-2032）：一次薬剤、二次薬剤
  • びまん皮膚硬化型全身性強皮症（DCSSC）治療薬のグローバル市場（2023～2030）
  • 筋萎縮性側索硬化症（ALS）治療薬のグローバル市場：産業動向、シェア、規模、成長、機会・予測（2023～2028）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP123 )"筋骨格系障害（MSD）治療薬のグローバル市場（2023-2032）：鎮痛薬、DMARD、コルチコステロイド、その他" (英文：Musculoskeletal Disorders Drugs Market By Drug Type (Analgesics, DMARDs, Corticosteroids, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。